StreetAlpha.app
Home › Stocks › ACXP

Acurx Pharmaceuticals, Inc. (ACXP)

$1.04
▲ +0.97%
LAST CLOSE · NOV 20

Acurx Pharmaceuticals develops new antibiotics for hard to treat bacterial infections, based in Staten Island, New York. It last closed at $1.04 on Nov 20, up 0.97% on the day. For the quarter ended Sep 2026, ACXP reported EPS of -$0.49. Over its last 8 reports the stock moved an average of 7.1% the session after earnings.

AI Auto Pilots
Is ACXP in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ACXP.

Key Stats

Last 12 months
Results
Net income
−$8.1M
EPS (diluted)
−$1.90
Valuation
Market cap
$6.3M
6.1M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$9.7M
At Sep 30
Shareholder equity
$7.3M
Shares outstanding
6.1M
At Nov 12
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$12.7M−$12.7MFY2021FY2022: −$12.1M−$12.1MFY2022FY2023: −$14.6M−$14.6MFY2023FY2024: −$14.1M−$14.1MFY2024FY2025: −$8.0M−$8.0MFY2025

From ACXP's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
May 13
2025 · next date not set yet
Reported EPS
-$0.49
Quarter ended Sep 2026
Year ago EPS
-$1.23
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$3.22Dec '24Mar 2025: -$2.15Mar '25Jun 2025: -$1.89Jun '25Sep 2025: -$1.23Sep '25Dec 2025: -$0.31Dec '25Mar 2026: -$0.62Mar '26Jun 2026: -$0.53Jun '26Sep 2026: -$0.49Sep '26Latest -$0.49
Revenue by quarter
Not enough quarters on file yet.
How ACXP moved after its last 8 reports
Average move the session after a report ±7.1%
May 13, 2025Time not announced−3.9%
Mar 18, 2025Time not announced−14.2%
Nov 13, 2024Time not announced−1.6%
Aug 9, 2024Time not announced−1.1%
May 15, 2024Time not announced+7.7%
Mar 18, 2024After the close−18.5%
Nov 14, 2023After the close+1.2%
Aug 14, 2023Time not announced−8.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ACXPStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ACXP
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ACXP

Technical Analysis

ACXP · as of the Nov 20 close · updated each morning
Downtrend

The stock sits between its 20 and 50 day averages. It is 79% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 46). The nearest support is the 20 day average at $1.03, and the nearest resistance the Pivot at $1.06.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 8.0%/day
Key levels
$7.5452 week high+625.0%
$1.86200 day average+78.8%
$1.32100 day average+26.9%
$1.1750 day average+12.5%
$1.12Swing high (Nov 2)+7.7%
$1.10Pivot R1+5.8%
$1.06Pivot+1.9%
$1.04Last close
$1.0320 day average−1.0%
$1.00Pivot S1−3.8%
$0.95Swing low (Nov 5)−8.7%
$0.9052 week low−13.5%
Indicators
RSI (14)46.24Middle of its rangeNeutral
MACD-0.05Above its signal lineBullish
Stochastic55.3Middle of its rangeNeutral
ADX (14)39.5Trending down
Williams %R-37.2Oversold below −80, overbought above −20Neutral
CCI (20)41.3Oversold below −100, overbought above 100Neutral
Rate of change−1.9%Change over 10 sessionsBearish
ATR (14)$0.08Typical daily range, 8.0% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for ACXP

What happened before

See how ACXP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ACXP usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ACXP has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ACXPHow many large options trades hit ACXP, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ACXP Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼6 buying vs 8 selling
  • ▲Held by funds +0.9 pts
  • ●Funds holding +0
  • ●No superinvestor moves
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding19190.0%
In funds' top 1000–
Held by funds3.0%2.0%+0.9 pts
New / increased3 / 32 / 3+20.0%
Reduced / sold out5 / 34 / 40.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ACXP institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ACXP Insider Trading

All filings →
Insider trading · 12 months
No open market trades in 12 months
Bought$00 buys · 0 insiders
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jan 6, 2025Jack H DeanDirectorBuy9,852$1.02$10K
Jan 6, 2025Robert J DelucciaDirectorBuy49,261$1.02$50K
Jan 6, 2025James J. DonohueDirectorBuy9,852$1.02$10K
Jan 6, 2025David P LuciPresident and CEOBuy49,261$1.02$50K
Jan 6, 2025Carl SailerDirectorBuy24,631$1.02$25K
Jan 6, 2025Joseph C ScodariDirectorBuy24,631$1.02$25K
Every insider buy and sale for ACXP over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ACXP insider trades →

From SEC Form 4 filings by ACXP's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACXP is in one of them and how their past ACXP trades turned out.

ACXP in the AI portfolios
Loading…

ACXP News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ACXP in an article yet. Here's the latest on the wider market.

ACXP in the news

About Acurx Pharmaceuticals

Acurx Pharmaceuticals is a biopharmaceutical company based in Staten Island, New York. It is developing a new class of small molecule antibiotics for bacterial infections that are hard to treat, including Clostridioides difficile infections, MRSA, and vancomycin resistant Enterococcus. Its lead candidate, ibezapolstat, works by blocking a bacterial enzyme called DNA pol IIIC and is in clinical trials. The company expects to partner with a larger drugmaker for later stage trials and commercialization, and its intended users are patients with these infections and the healthcare providers who treat them.

Headquarters
Staten Island, NY